3TC lamivudine combined with AZT data

BCHXF (Laval, Quebec) reported results of a European Phase II/III trial in 129 patients, showing sustained effects of combined therapy on surrogate markers.

As presented at the European Conference on Clinical Aspects and Treatment of HIV Infection in Copenhagen, the combination gave sustainable effects on CD4 counts and viral load in 26 patients for two years. ...